{"TopicDetails": {"type": 0, "ccm2Id": 31107109, "cftId": 0, "identifier": "IMI2-2019-17-03", "title": "Intelligent prediction and identification of environmental risks posed by human medicinal products ", "publicationDateLong": 1548115200000, "callIdentifier": "H2020-JTI-IMI2-2019-17-two-stage", "callTitle": "H2020-JTI-IMI2-2019-17-two-stage", "callccm2Id": 31107110, "allowPartnerSearch": true, "workProgrammepart": {"id": 272551, "ccm_id": 31107169, "wp_part": "H2020-JTI-IMI-2019", "wp_year": "H2020-JTI-IMI-2019", "wp_title": "H2020-JTI-IMI-2019", "wp_website": "http://www.imi.europa.eu/", "wp_document": "https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/AWP_and_Budget_2019_adopted_on_12_December_2018.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}], "topicMGAs": [], "tags": ["Environmental risks", "IMI2", "Patient", "Joint Undertaking", "H2020-JTI-IMI2-2019-17-two-stage", "Intelligent prediction and identification of environmental risks posed by human medicinal products", "IMI2 JU", "IMI2-2019-17-03", "Innovative Medicines Initiative"], "keywords": ["Toxicology", "Pharmaceuticals", "Pharmacology and pharmacy", "Environmental toxicology at the population and eco"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "22 January 2019", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["25 April 2019", "07 November 2019"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3294794": [{"action": "IMI2-2019-17-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "22 January 2019", "deadlineModel": "two-stage", "deadlineDates": ["25 April 2019", "07 November 2019"], "budgetYearMap": {"2019": 83894139}, "budgetTopicActionMap": {}}, {"action": "IMI2-2019-17-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "22 January 2019", "deadlineModel": "two-stage", "deadlineDates": ["25 April 2019", "07 November 2019"], "budgetYearMap": {"2019": 83894139}, "budgetTopicActionMap": {}}, {"action": "IMI2-2019-17-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "22 January 2019", "deadlineModel": "two-stage", "deadlineDates": ["25 April 2019", "07 November 2019"], "budgetYearMap": {"2019": 83894139}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2019"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>Pharmaceuticals are present in the environment as a consequence of patient use, manufacture, and improper disposal. They predominantly enter the aquatic environment via patient use. In the European Union (EU) an environmental risk assessment (ERA) is required as part of the marketing application and approval for new drugs. Currently the ERA is conducted late in drug development and often parallel to Phase III clinical trials and after significant investment.</p><p>The growing regulatory and scientific concerns regarding pharmaceuticals in the environment have reached the point where some stakeholders are advocating:</p><ul level=\"0\"><li>the inclusion of environmental hazard and risk within the patient-benefit evaluation that underpins the marketing authorisation of a drug;</li><li>a catch-up scheme for medicines authorised for use prior to 2006 that lack comprehensive environmental assessments;</li><li>increased transparency of environmental data;</li><li>increased consideration of environmental properties in drug development (i.e. greener drug design).</li> </ul><p>However, without validated tools to predict environmental risk earlier in drug development these stakeholder expectations could impact the availability of life-changing medicines to patients within Europe and impact the competitiveness of the industry.</p><p>For complete information, please see the IMI2 Call 17 topic text.</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The overall aim of this project is to apply innovative approaches to ensure the environmental safety of human medicinal products such that both (i) environmental concerns do not become a barrier to patient access to medicines, and (ii) the intended use of medicines does not pose an unacceptable risk to the environment. </p><p>This project aims to refine, extend, validate and implement approaches to the prioritisation and testing of new APIs to ensure the environmental safety of established medicinal products. </p><p>For complete information, please see the IMI2 Call 17 topic text.</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>This project aims to develop an EU-wide pharmaceutical ecotoxicology database which will:</p><ul level=\"0\"><li>help all stakeholders better understand the risks posed to the environment by human medicinal products;</li><li>allow environmental chemists to present their monitoring work in the context of risk;</li><li>reduce duplication of environmental testing across the industry. The database will also enable the environmental risks of a human medicinal product to be actively managed across its product life cycle and help facilitate the industry extended environmental risk assessment (eERA) model.</li> </ul><p>The availability of tools and models has the potential to deliver significant animal welfare benefits and cost savings without compromising environmental protection, for example, the pharmaceutical industry could save more than EUR 500 million.</p><p>Applicants should also indicate how their proposal will impact the competitiveness and industrial leadership of the European Union by, for example, engaging suitable small and medium-sized enterprises (SMEs).</p><p>For complete information, please see the IMI2 Call 17 topic text.</p>\n", "conditions": "<p><b><span style=\"font-size: 9pt; line-height: 115%; font-family: Arial, sans-serif;\">Please read carefully all provisions below before the preparation of your application.</span></b></p>\r\n<p><b><span style=\"font-size: 9pt; line-height: 115%; font-family: Arial, sans-serif;\"> The IMI2 JU 17th Call for proposals topics text as well as the Call Conditions are available <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche19-17-imi2-ju_en.pdf\" target=\"_blank\">here</a></span></b></p>\r\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The budget breakdown for this Call is given at the end of the Call topics text, in the <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche19-17-imi2-ju_en.pdf\" target=\"_blank\">Call conditions</a>&nbsp;</span></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">section, as well as the following information :</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><span style=\"color: rgb(0, 51, 102);\"><strong>1.&nbsp;&nbsp; Eligible countries:</strong></span>&nbsp;described in article 10(2) of the&nbsp;<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Rules for participation in Horizon 2020</a>&nbsp;and in article 1 of the&nbsp;<a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.<b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;<o:p></o:p></span></b></p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>2.&nbsp;&nbsp; Eligibility and admissibility conditions:</strong></span> described in the <strong><a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/IMI2_ManualForSubmission_v1.7_November2018.pdf\" target=\"_blank\">IMI2 Manual for evaluation, submission and grant award</a>.</strong>  See also the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Proposal page limits and layout:</strong></span> Please refer to Part B of the proposal template in the submission tool below.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>3.&nbsp;&nbsp; Evaluation: </strong></span><br />\r\nSubmission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the <strong><a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/IMI2_ManualForSubmission_v1.7_November2018.pdf\" target=\"_blank\">IMI2 Manual for submission, evaluation and grant award</a></strong>. See also the proposal templates for your specific action in section 5, below.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>4.&nbsp;&nbsp; Indicative time for evaluation and grant agreement: </strong></span><br />\r\nNotification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.<br />\r\nNotification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.</p>\r\n<p>Signature of grant agreements: maximum 3 months from the date of informing successful applicants.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>5.&nbsp;&nbsp; Proposal templates, evaluation forms and model grant agreements (MGA):</strong></span></p>\r\n<p><strong>IMI2 Research and Innovation Action (IMI2-RIA) </strong><strong>and Innovation Action (IMI2-IA):</strong></p>\r\n<p>Proposal templates are available after entering the submission tool<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\" target=\"_blank\"> Standard evaluation form</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\" target=\"_blank\">IMI2 Model Grant Agreement</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies_2018-2020_en.pdf\" target=\"_blank\">Clinical trial template</a>&nbsp;&ndash; the Clinical Trial template is compulsory at stage 2 only !</p>\r\n<p>&nbsp;</p>\n<p><strong><span style=\"color: rgb(0, 51, 102);\">6.&nbsp;&nbsp; Open access must be granted to all scientific publications </span></strong>resulting from Horizon 2020 actions.</p>\r\n<p>Where relevant, proposals should also provide information on how the  participants will manage the research data generated and/or collected  during the project, such as details on what types of data the project  will generate, whether and how this data will be exploited or made  accessible for verification and re-use, and how it will be curated and  preserved.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Open access to research data</strong></span><br />\r\nThe Open Research Data Pilot has been extended to cover all Horizon 2020  topics for which the submission is opened on 26 July 2016 or later.  Projects funded under this topic will therefore by default provide open  access to the research data they generate, except if they decide to  opt-out under the conditions described in <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-l-openaccess_en.pdf\" target=\"_blank\">Annex L of the H2020 main Work Programme</a>. Projects can opt-out at any stage, that is both before and after the grant signature.</p>\r\n<p>Note that the evaluation phase proposals will not be evaluated more  favourably because they plan to open or share their data, and will not  be penalised for opting out.</p>\r\n<p>Open research data sharing applies to the data needed to validate the  results presented in scientific publications. Additionally, projects  can choose to make other data available open access and need to describe  their approach in a Data Management Plan.</p>\r\n<p>Projects need to create a Data Management Plan (DMP), except if they  opt-out of making their research data open access. A first version of  the DMP must be provided as an early deliverable within six months of  the project and should be updated during the project as appropriate. The  Commission already provides guidance documents, including a template  for DMPs. See the <a href=\"https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm\" target=\"_blank\">Online Manual</a>.</p>\r\n<p>Eligibility of costs: costs related to data management and data  sharing are eligible for reimbursement during the project duration.</p>\r\n<p>The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.</p>\r\n<p>&nbsp;</p>\n<p>Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>7. Additional documents:</strong></span></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\" target=\"_blank\">Summary of the most relevant provisions for participating in IMI2 actions</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp19-imi2_en.pdf\" target=\"_blank\">2019 Annual Work Plan and Budget</a><br />\r\n<br />\r\n<a href=\"https://www.imi.europa.eu/get-involved/regulators-htas-and-payers\" target=\"_blank\">IMI2 Regulators Guidance tool for researchers</a></p>\r\n<p><a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:JOL_2014_174_R_0003\" target=\"_blank\">IMI JU derogation to H2020 Rules for Participation</a> &nbsp;<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Horizon 2020 Rules for Participation&nbsp;</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/fp/h2020-eu-establact_en.pdf\" target=\"_blank\">Horizon 2020 Regulation of Establishment </a><br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/sp/h2020-sp_en.pdf\" target=\"_blank\">Horizon 2020 Specific Programme</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"color: rgb(0, 51, 102);\"><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\" target=\"_blank\"><strong>H2020 Online Manual</strong></a> </span>is your guide on the procedures from proposal submission to managing your grant.</p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;categories=;programme=null;actions=;keyword=\" target=\"_blank\"><strong><span style=\"color: rgb(0, 51, 102);\">Funding and tenders Portal FAQ</span></strong></a> &ndash; Submission of proposals.</p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>National Contact Points (NCP)</strong></span></a> - contact your NCP for further assistance in your national language(s).</p>\r\n<p><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Research Enquiry Service</strong></span></a> &ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong><a href=\"http://een.ec.europa.eu/\" target=\"_blank\">Enterprise Europe Network</a> </strong></span>&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.</p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>IT Helpdesk</strong></span></a><strong> </strong>- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Ethics</strong></span> &ndash; for compliance with ethical issues, see the <a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\" target=\"_blank\">Online Manual</a> and <a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\" target=\"_blank\">Science and Society Portal</a></p>\r\n<p><a href=\"http://www.iprhelpdesk.eu/\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>European IPR Helpdesk</strong></span></a> assists you on intellectual property issues</p>\r\n<p><a href=\"https://www.cencenelec.eu/research/Pages/default.aspx\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>CEN</strong></span><strong> <span style=\"color: rgb(0, 51, 102);\">and</span> </strong><span style=\"color: rgb(0, 51, 102);\"><strong>CENELEC</strong></span></a>, the <span style=\"color: rgb(0, 51, 102);\"><strong>European Standards Organisations</strong></span>, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <span style=\"color: rgb(0, 0, 255);\">research@cencenelec.eu</span></p>\r\n<p><a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>The European Charter for Researchers and the Code of Conduct for their recruitment</strong></span></a></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Partner Search Services</strong></span></a> help you find a partner organisation for your proposal.</p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size: 10pt; line-height: 115%; font-family: Arial, sans-serif; color: rgb(40, 151, 183); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><span style=\"color:#2897B7\"><a href=\"https://www.imi.europa.eu/about-imi/governance/states-representatives-group\" target=\"_blank\">IMI2 States Representative Group (SRG)</a></span></span></b></span><span style=\"font-size: 10pt; line-height: 115%; font-family: Arial, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">&nbsp;&ndash; contact you SRG member for assistance.</span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size: 10pt; line-height: 115%; font-family: Arial, sans-serif; color: rgb(40, 151, 183); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><a href=\"mailto:applicants@imi.europa.eu\" target=\"_blank\"><span style=\"color:#2897B7\">IMI2 JU&nbsp;</span><span style=\"color:#2897B7\">Applicants Helpdesk</span></a></span></b></span><span style=\"font-size: 10pt; line-height: 115%; font-family: Arial, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\">&nbsp;<strong>&ndash; </strong>contact the IMI2 Programme Office</span></p>", "sepTemplate": "<p>To access the Electronic Sumission Service, please click on the submission-button next to the type of action that corresponds to your proposal. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [{"callId": 52392644160, "id": 165934014, "title": "IMI2 Call 17 stage 1 - Flash Call Info Report ", "sectionId": 52392644160, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 221101, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2019-17-03/1860145-imi2_call_17_-_flash_call_info_report_-_stage_1_en.pdf", "id": 1860145, "fileName": "IMI2 Call 17 - Flash Call Info report - stage 1_EN.pdf", "common": false, "crc32": 3543473631}]}, {"callId": 52392644160, "id": 165934015, "title": "IMI2 Call 17 stage 2 - Flash Call Info Report ", "sectionId": 52392644160, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 219883, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2019-17-03/1877608-imi2_call_17_-_flash_call_info_report_-_stage_2_en.pdf", "id": 1877608, "fileName": "IMI2 Call 17 - Flash Call Info report - stage 2_en.pdf", "common": false, "crc32": 3564226247}]}], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Jul 4, 2019 11:17:19 AM", "lastChangeDate": "Jul 4, 2019 11:17:19 AM", "content": "<p>An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2019-17-01/1860145-imi2_call_17_-_flash_call_info_report_-_stage_1_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 17 &ndash; first stage</a>) is now available under the call &lsquo;Additional documents&rsquo; tab</p>"}, {"approvalDate": "Apr 26, 2019 11:44:46 AM", "lastChangeDate": "Apr 26, 2019 11:44:46 AM", "content": "<p><strong>Proposal numbers</strong></p>\r\n<p>Stage 1 submission deadline for the Call<strong> IMI2-2019-17-two-stage </strong>has closed on the 25 April 2019.</p>\r\n<p>10 proposals have been submitted.</p>\r\n<p>The breakdown per topic is:</p>\r\n<p>IMI2-2019-17-01: 4</p>\r\n<p>IMI2-2019-17-02: 3</p>\r\n<p>IMI2-2019-17-03: 3</p>\r\n<p>Evaluation results for stage 1 are expected to be communicated in July 2019.</p>"}, {"approvalDate": "Jan 22, 2019 12:30:00 AM", "lastChangeDate": "Jan 22, 2019 12:30:00 AM", "content": "The submission session is now available for: IMI2-2019-17-03(IMI2-RIA), IMI2-2019-17-01(IMI2-RIA), IMI2-2019-17-02(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}